| Price | Lot Size | Issue Date | Issue Size |
|---|---|---|---|
| ₹768 to ₹807 | 18 | 10th Aug, 2026 – 12th Aug, 2026 | ₹940 Cr |
Molbio Diagnostics Ltd
Molbio Diagnostics Limited (MDL) is a molecular diagnostics company that develops and manufactures rapid point-of-care (POC) diagnostic solutions for infectious and non-communicable diseases. Its business is built around the proprietary Truenat platform, a portable, battery-operated molecular testing system that enables healthcare providers to diagnose diseases in about one hour, even in locations with limited laboratory infrastructure. The Truenat platform comprises two devices that work together. A patient’s sample is first processed in Trueprep, which automatically extracts the genetic material (DNA/RNA). The processed sample is then placed on a disease-specific Truenat test chip and inserted into Truelab, a compact real-time PCR (Polymerase Chain Reaction) analyser that detects the disease. By simply changing the test chip, the same workstation can diagnose multiple diseases. The platform supports 43 diagnostic tests (assays) covering 30 diseases, including Tuberculosis (TB), COVID-19, HIV, Hepatitis B & C and HPV. Notably, its TB test is one of only two rapid molecular diagnostics globally endorsed by the World Health Organization (WHO) for initial TB diagnosis and rifampicin resistance detection. MDL follows a razor-and-blade business model, selling Trueprep and Truelab workstations to hospitals, diagnostic laboratories, government healthcare programmes and international health agencies, while generating recurring revenue through proprietary Truenat test chips and reagents that work exclusively on its devices. Consequently, every installed workstation creates recurring demand for consumables, with test kits contributing 74% of FY26 revenue, while devices accounted for 14.5%. The company derives 85% of its revenue from Indian government agencies and international health institutions, while TB diagnostics contributed 70.2% of product revenue, highlighting its strong positioning in national disease control programmes. MDL has a presence in over 90 countries, although 90% of FY26 revenue was generated from India. Operations are supported by six manufacturing facilities with an annual capacity of 5,400 devices and 39 million test kits. Innovation is driven by its R&D subsidiary Bigtec, where 153 researchers, including 136 scientists, support product development. The company invested Rs. 875 million, equivalent to 6.1% of FY26 revenue, towards R&D and holds a portfolio of 207 patents globally. Supported by experienced promoters, MDL has established itself as a leading innovator in the molecular diagnostics industry.
Objective of Molbio Diagnostics Ltd
The Offer comprises a fresh issue of Rs. 200 crores and an offer for sale of Rs. 740 crores. The company proposes to utilise the net proceeds from the fresh issue towards:
- Setting up R&D and centre of excellence infrastructure, along with associated office space;
- Purchase of plant, machinery and equipment for Goa unit I, Goa unit II and Visakhapatnam unit; and
- General corporate purposes.
Rationale To Molbio Diagnostics Ltd
Investment Rationale
Expanding product portfolio supported by R&D, manufacturing and geographic expansion
MDL’s Truenat platform is positioned to benefit from the growing adoption of decentralised molecular diagnostics by enabling PCR based testing closer to the point of care, particularly in settings with limited laboratory infrastructure. The platform currently supports testing across 30 diseases through 43 assays, with the company expanding beyond its established tuberculosis franchise into areas such as Hepatitis, HIV, HPV and other infectious and non-communicable diseases. This expansion increases the potential utilisation of its existing Truenat installed base and supports the recurring consumables led nature of the business. The company’s ability to adapt its platform across disease categories was also demonstrated during the COVID-19 period, when devices deployed under the tuberculosis programme were repurposed for COVID testing. MDL’s product expansion is supported by its in house R&D capabilities through Bigtec, which has enabled the development of new diagnostic platforms and assays. The company is also investing in the Centre of Excellence which is a dedicated facility that the company plans to establish to strengthen its R&D and innovation capabilities, while planned capital expenditure is expected to strengthen manufacturing capacity across its Goa and Visakhapatnam facilities. In parallel, MDL is expanding its geographical presence, with its Truenat platform already deployed across international markets and plans to increase penetration in regions including Africa and Southeast Asia. The company has also expanded into adjacent diagnostic segments such as radiology and digital pathology through acquisitions.
Scalable business model supported by recurring revenues and strategic expansion
MDL’s Truenat platform follows a closed system model comprising Trueprep extraction and Truelab analyser devices that are designed to operate with Truenat test kits. Once the devices are installed, healthcare providers can conduct multiple disease tests using the company’s expanding range of kits, supporting recurring demand for consumables while increasing the utility of the installed base. The platform’s ability to accommodate a growing range of infectious and non-communicable disease tests also provides scope to expand its addressable market. MDL operates in an oligopolistic molecular diagnostics market with high entry barriers, with the Truenat platform having undergone an extended R&D and certification process and its TB test receiving WHO endorsement for initial diagnosis and rifampicin resistance detection. The company has also expanded its capabilities through acquisitions and strategic collaborations. The acquisition of Prognosys has added radiology and digital imaging capabilities, including ultraportable X-ray systems, while its investment in OptraScan has expanded MDL’s presence in digital pathology through scanners, AI-enabled analysis and telepathology solutions. In addition, collaborations across TB screening, multiplex molecular testing, breast health screening and veterinary diagnostics allow MDL to broaden its product offerings and extend its point-of-care capabilities into adjacent applications. These initiatives provide additional avenues for product and geographical expansion while leveraging MDL’s existing diagnostics platform and commercial capabilities.
Valuation of Molbio Diagnostics Ltd
MDL Diagnostics Limited (MDL) is a differentiated molecular diagnostics company with a proprietary point-of-care (POC) platform that follows a closed-system business model, generating recurring revenue through proprietary test kits and consumables. Its Truenat platform, deployed across 90+ countries, has established a strong position in decentralised molecular diagnostics, while its WHO-endorsed TB test and in-house R&D capabilities create high technological and regulatory entry barriers. The company is well positioned to benefit from the growing adoption of molecular diagnostics through an expanding portfolio of 43 diagnostic tests across 30 diseases, driving higher utilisation of its installed base and recurring consumables revenue. Continued investments in R&D, manufacturing capacity and international expansion, along with strategic acquisitions in adjacent diagnostic segments, provide multiple long-term growth drivers. Financial performance has remained strong, with revenue, EBITDA and PAT registering CAGRs of 31.4%, 33.2% and 40.2%, respectively, during FY24-FY26. Revenue grew 41.7% YoY in FY26, while test kit volumes nearly doubled from 8.8 million in FY24 to 17.6 million, highlighting the scalability of its recurring revenue model. Although EBITDA margin moderated to 22.6% in FY26 from 25.0% in FY25 due to acquisitions and growth investments, the company’s pre-R&D EBITDA margin remained a healthy 28.6%, reflecting the underlying profitability of its core business. At the upper price band of Rs. 807, the issue is valued at 54.6x FY26 earnings, compared with the listed peer average of 64.9x. While the business remains exposed to customer concentration, with 84.6% of finished goods revenue derived from government agencies and international health institutions, its differentiated technology platform, recurring revenue model and high entry barriers support its premium positioning. Accordingly, we recommend a “SUBSCRIBE” rating for the issue with a long-term investment horizon.
What is the Molbio Diagnostics Ltd IPO?
The initial public offer (IPO) of Molbio Diagnostics Ltd an early investment opportunity in. A stock market investor can buy Molbio Diagnostics Ltd IPO shares by applying in IPO before All Molbio Diagnostics Ltd shares get listed at the stock exchanges. An investor could invest in Molbio Diagnostics Ltd for short term listing gain or a long term.
How to apply for the Molbio Diagnostics Ltd IPO through StoxBox?
To apply for the Molbio Diagnostics Ltd IPO through StoxBox one can apply from the website and also from the app. Click here
When will the Molbio Diagnostics Ltd IPO open?
Molbio Diagnostics Ltd IPO is opening on 10th Aug 2026. Apply Now
What is the lot size of the Molbio Diagnostics Ltd IPO?
The Lot Size of Molbio Diagnostics Ltd 18 equity shares. Login to your account now.
When is the Molbio Diagnostics Ltd IPO allotment date?
The allotment Date for Molbio Diagnostics Ltd IPO is 13th Aug 2026. Login to your account now.
When is the Molbio Diagnostics Ltd IPO listing date?
The listing Date for Molbio Diagnostics Ltd is 17th Aug 2026. Login to your account now
What is the minimum investment required for the Molbio Diagnostics Ltd IPO?
In the Retail segment the minimum investment required is Rs 14,526 Login to your account now
What is the maximum investment allowed for Molbio Diagnostics Ltd IPO?
In the Retail segment the maximum investment requirement Rs 1,88,838 Login to your account now
What are the risks associated with investing in the Molbio Diagnostics Ltd IPO?
- Heavy reliance on government spending: Government agencies and international aid organisations contributed 85% of FY26 finished goods revenue. Any reduction in public healthcare spending, policy changes or funding constraints could adversely impact revenue and growth.
- Product concentration towards TB: Tuberculosis diagnostic test kits accounted for 70% of FY26 finished goods revenue. Any decline in TB testing demand, changes in government programmes or adoption of alternative technologies could materially impact the company’s financial performance.
- R&D and regulatory risk: The company relies on continuous R&D to expand its diagnostic portfolio. Delays in product development or failure to obtain regulatory approvals could impact new product launches, growth prospects and returns on R&D investments.
When will the Molbio Diagnostics Ltd IPO shares be credited to my Demat account?
The Molbio Diagnostics Ltd will be credited to the account on allotment date which is 13th Aug 2026. Login to your account now
Where can I find the Molbio Diagnostics Ltd IPO prospectus?
The prospectus of Molbio Diagnostics Ltd IPO prospectus can be found on the website of SEBI, NSE and BSE
